Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors
Public ClinicalTrials.gov record NCT06714617. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of BL-M17D1 in Subjects With HER2-Expressing or HER2-Mutant Advanced or Metastatic Solid Tumors
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The objective of this study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of BL-M17D1 in patients with HER2-Expressing or HER2-Mutant Advanced or Metastatic Solid Tumors.
Study identification
- NCT ID
- NCT06714617
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 3 participants
Conditions and interventions
Conditions
- Breast Cancer Stage III
- HER2-positive Metastatic Breast Cancer
- Unresectable Breast Carcinoma
- Her2-Positive
- HER2 Gene Mutation
- Gastroesophageal-junction Cancer
- Non Small Cell Lung Cancer
- Endometrial Neoplasms
- Peritoneal Cancer
- Fallopian Tube Cancer
- Ovarian Cancer
- Urothelial Carcinoma Bladder
- Solid Tumor, Adult
- Gastric Cancer
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 10, 2025 (Actual)
- Primary completion
- Jan 30, 2026 (Actual)
- Completion
- Jan 30, 2026 (Actual)
- Last update posted
- Sep 22, 2026
2025 – 2026
United States locations
- U.S. sites
- 9
- U.S. states
- 7
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| SCRI-Denver HealthOne | Denver | Colorado | 37203 | — |
| Yale Cancer Center | New Haven | Connecticut | 06510 | — |
| SCRI-Florida Cancer Center Specialists Lake Mary | Lake Mary | Florida | 32746 | — |
| Hematology Oncology Associates of the Treasure Cost | Port Saint Lucie | Florida | 34952 | — |
| SCRI-Florida Cancer Center Specialists Sarasota | Sarasota | Florida | 34236 | — |
| Dana-Farber Cancer Institute | Boston | Massachusetts | 02215 | — |
| SCRI-Sidney Kimmel Cancer Center | Philadelphia | Pennsylvania | 19107 | — |
| SCRI-Oncology Partners | Nashville | Tennessee | 37203 | — |
| NEXT Oncology | Fairfax | Virginia | 22031 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06714617, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 22, 2026 · Synced Oct 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT06714617 live on ClinicalTrials.gov.